5PSQ-030 Effectiveness and safety of semaglutide in patients with type 2 diabetes: real-world usage data
Year: 2025
Type: conference-paper
Study design: Observational Study
Abstract: Background and Importance Semaglutide, a GLP1-analogue (aGLP1), is funded in our country for treating type 2 diabetes (DM2) in obese patients (BMI ≥30 kg/m2) with inadequate glycaemic control, in combination with oral antidiabetics (ADO) and/or insulin. Both oral and subcutaneous forms have shown efficacy and safety. Aim and Objectives To evaluate the prescription profile, effectiveness, and safety of semaglutide in DM2 patients treated for over 1 year without prior aGLP1 therapy. Material and Methods A single-centre retrospective study conducted in June 2023 at a second-level hospital, including patients treated with semaglutide for over 1 year. Variables recorded: demographics (sex, age), anthropometrics (weight, height), clinical factors (cardiovascular disease (CVD), chronic kidney disease (CKD)), analytical measures (glucose, HbA1c, total cholesterol (TC), LDL, triglycerides (TG)), and pharmacotherapeutic variables (prior ADO/insulin, concomitant statins). Safety was assessed by gastrointestinal (GI) symptoms and cardiovascular events (stroke, myocardial infarction). Funding criteria reviewed: 1) DM2 diagnosis, 2) BMI ≥30 kg/m2, 3) prior ADO/insulin, 4) poor glycaemic control. Prescriptions were optimal if all criteria were met. Quantitative variables are presented as mean ± SD, and qualitative as frequency and percentage. Results The study included 41 DM2 patients (60 ± 11 years; 61% male) treated for 696 ± 309 days. 27% had CVD, 10% CKD ≥ G3, and 76% had HbA1c ≥6.5%. 88% had prior ADO/insulin treatment, 93% concomitant, and 66% took statins. Baseline and final weight (kg) and BMI (kg/m2): 103 ± 22; 36 ± 9 and 93 ± 20; 33 ± 7, respectively. Baseline and 1-year follow-up values for glucose (mg/dl), HbA1c (%), TC (mg/dl), LDL (mg/dl), and TG (mg/dl) were: 153 ± 62; 8 ± 2; 182 ± 44; 98 ± 32; 243 ± 275 and 115 ± 39; 6 ± 1; 154 ± 41; 84 ± 32; 163 ± 111, respectively. HbA1c decreased by 2%, with a 10 kg weight loss and lipid profile improvement. GI symptoms occurred in 12% of patients, with no CVD events reported. Optimal prescription was seen in 73%. Conclusion and Relevance Semaglutide’s effectiveness and safety in routine practice align with clinical trial results. Limitations include small sample size and non-adherence to funding criteria, prompting a hospital compliance circuit. References and/or Acknowledgements Conflict of Interest No conflict of interest
Authors: C Lasala Aza, C Huelamo Moruno, S Guijarro Herrera, I Moya Carmona
Institution: Hospital Clínico Universitario Virgen de la Victoria
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4408376751